The p53 pathway and its inactivation in neuroblastoma - PubMed (original) (raw)
Review
The p53 pathway and its inactivation in neuroblastoma
Deborah A Tweddle et al. Cancer Lett. 2003.
Abstract
Early studies of p53 in neuroblastoma reported infrequent mutations in tumours and cell lines. Cytoplasmic sequestration was later proposed as an alternative mechanism of inactivation, but many studies have since reported an intact p53 pathway in neuroblastoma cell lines, as detected by nuclear p53 accumulation after DNA damage, intact DNA binding, transcriptional activation of target genes and the induction of apoptosis. In some MYCN amplified cell lines however, an irradiation induced G(1) arrest does not occur, despite the presence of normal p53. Neuroblastoma usually responds to chemotherapy but frequently relapses, and there is evidence from tumours, and cell lines that p53 inactivation via mutation or MDM2 amplification occurs at relapse and is sometimes associated with multidrug resistance. If p53 inactivation occurs frequently in relapsed tumours it may be appropriate to include p53 independent therapies in the initial management of high-risk neuroblastoma.
Similar articles
- p53 cellular localization and function in neuroblastoma: evidence for defective G(1) arrest despite WAF1 induction in MYCN-amplified cells.
Tweddle DA, Malcolm AJ, Cole M, Pearson AD, Lunec J. Tweddle DA, et al. Am J Pathol. 2001 Jun;158(6):2067-77. doi: 10.1016/S0002-9440(10)64678-0. Am J Pathol. 2001. PMID: 11395384 Free PMC article. - MYCN-directed centrosome amplification requires MDM2-mediated suppression of p53 activity in neuroblastoma cells.
Slack AD, Chen Z, Ludwig AD, Hicks J, Shohet JM. Slack AD, et al. Cancer Res. 2007 Mar 15;67(6):2448-55. doi: 10.1158/0008-5472.CAN-06-1661. Cancer Res. 2007. PMID: 17363562 - The role of MYCN in the failure of MYCN amplified neuroblastoma cell lines to G1 arrest after DNA damage.
Bell E, Premkumar R, Carr J, Lu X, Lovat PE, Kees UR, Lunec J, Tweddle DA. Bell E, et al. Cell Cycle. 2006 Nov;5(22):2639-47. doi: 10.4161/cc.5.22.3443. Epub 2006 Nov 15. Cell Cycle. 2006. PMID: 17172827 - Escape from p53-mediated tumor surveillance in neuroblastoma: switching off the p14(ARF)-MDM2-p53 axis.
Van Maerken T, Vandesompele J, Rihani A, De Paepe A, Speleman F. Van Maerken T, et al. Cell Death Differ. 2009 Dec;16(12):1563-72. doi: 10.1038/cdd.2009.138. Epub 2009 Sep 25. Cell Death Differ. 2009. PMID: 19779493 Review. - MDM2 as MYCN transcriptional target: implications for neuroblastoma pathogenesis.
Slack A, Lozano G, Shohet JM. Slack A, et al. Cancer Lett. 2005 Oct 18;228(1-2):21-7. doi: 10.1016/j.canlet.2005.01.050. Cancer Lett. 2005. PMID: 15927364 Review.
Cited by
- Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program.
Carol H, Reynolds CP, Kang MH, Keir ST, Maris JM, Gorlick R, Kolb EA, Billups CA, Geier B, Kurmasheva RT, Houghton PJ, Smith MA, Lock RB. Carol H, et al. Pediatr Blood Cancer. 2013 Apr;60(4):633-41. doi: 10.1002/pbc.24235. Epub 2012 Jul 2. Pediatr Blood Cancer. 2013. PMID: 22753001 Free PMC article. - p53 oligomerization status as an indicator of sensitivity of p53-wildtype neuroblastomas to the combination of DNA damaging agent and Chk1 inhibitor.
Levesque AA, Pappalardo RM, Puli P, Enzor LA, Angeles C. Levesque AA, et al. PLoS One. 2022 Feb 10;17(2):e0263463. doi: 10.1371/journal.pone.0263463. eCollection 2022. PLoS One. 2022. PMID: 35143532 Free PMC article. - Anti-cancer effects of JKA97 are associated with its induction of cell apoptosis via a Bax-dependent and p53-independent pathway.
Luo W, Liu J, Li J, Zhang D, Liu M, Addo JK, Patil S, Zhang L, Yu J, Buolamwini JK, Chen J, Huang C. Luo W, et al. J Biol Chem. 2008 Mar 28;283(13):8624-33. doi: 10.1074/jbc.M707860200. Epub 2008 Jan 23. J Biol Chem. 2008. PMID: 18218619 Free PMC article. - Genome wide expression profiling of p53 regulated miRNAs in neuroblastoma.
Rihani A, Van Goethem A, Ongenaert M, De Brouwer S, Volders PJ, Agarwal S, De Preter K, Mestdagh P, Shohet J, Speleman F, Vandesompele J, Van Maerken T. Rihani A, et al. Sci Rep. 2015 Mar 12;5:9027. doi: 10.1038/srep09027. Sci Rep. 2015. PMID: 25762502 Free PMC article. - Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells.
Michaelis M, Rothweiler F, Barth S, Cinatl J, van Rikxoort M, Löschmann N, Voges Y, Breitling R, von Deimling A, Rödel F, Weber K, Fehse B, Mack E, Stiewe T, Doerr HW, Speidel D, Cinatl J Jr. Michaelis M, et al. Cell Death Dis. 2011 Dec 15;2(12):e243. doi: 10.1038/cddis.2011.129. Cell Death Dis. 2011. PMID: 22170099 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous